Published On : July 2026
The Actinium-225 value chain is shaped by two distinct groups of companies: isotope producers responsible for manufacturing and supplying Ac-225, and targeted alpha therapy developers who formulate, trial, and eventually commercialize Ac-225-based radiopharmaceuticals. A structural understanding of who operates where in this chain, and how the two groups increasingly partner, is essential context for investors, business development teams, and competitive intelligence analysts tracking this market.
Unlike many pharmaceutical markets, where a single company typically controls both raw material and finished product, the Ac-225 landscape is structurally split between upstream producers and downstream developers, with a comparatively small number of organizations spanning both roles. This split exists because isotope production requires specialized nuclear infrastructure, accelerators, reactors, or thorium-extraction facilities, that most biopharmaceutical companies do not operate themselves.
This structural separation is precisely what makes supply relationships so commercially important across the broader Ac-225 supply and therapy market: developers cannot simply scale production internally, and producers depend on a growing base of developer demand to justify continued capacity investment.
NorthStar Medical Radioisotopes has established itself as one of the more prominent Ac-225 producers, with a stated focus on accelerator-based, non-carrier-added production intended to help close the global supply gap. ITM Isotope Technologies Munich operates across multiple therapeutic radioisotopes, including Ac-225, leveraging established European radiopharmaceutical manufacturing infrastructure. Eckert & Ziegler similarly maintains a diversified radioisotope production portfolio with Ac-225 supply capabilities positioned alongside its broader nuclear medicine business.
Orano Med brings a production heritage rooted in the broader Orano nuclear group, while TerraPower Isotopes, NRG PALLAS, PanTera, and Nusano each represent newer or specialized entrants pursuing distinct production routes, spanning reactor-assisted, accelerator-based, and other emerging technologies. Together, this producer group defines the practical ceiling on how much clinical-grade Ac-225 the market can access at any given time. Readers wanting detail on the production methods these isotope producers operate, including how each route affects purity and scalability, can review our full production methods and supply technologies analysis.
MARKET SHIFT
The producer base has broadened meaningfully over the past several years, moving beyond a handful of legacy Thorium-229 extraction operators.
Newer entrants pursuing accelerator-based and reactor-assisted routes are gradually diversifying where global supply originates.
This diversification is a key factor supporting the market's ability to keep pace with expanding clinical demand.
Bayer Radiology has built a substantial presence in targeted alpha therapy, extending its existing radiopharmaceutical portfolio into Ac-225-based development. Fusion Pharmaceuticals and RayzeBio, the latter having been acquired by a major pharmaceutical company, both maintain active Ac-225 development programs spanning multiple oncology indications. Telix Pharmaceuticals and Curium Pharma similarly maintain Ac-225-focused development activity alongside broader radiopharmaceutical portfolios.
RadioMedix, Actinium Pharmaceuticals, Alpha Tau Medical, ARTBIO, and POINT Biopharma round out a developer landscape that spans from smaller, pipeline-focused biotechnology companies to larger organizations with diversified radiopharmaceutical programs. Each is pursuing the cancer indications these developers are targeting somewhat differently, reflecting the broadening application landscape across prostate cancer, neuroendocrine tumors, hematologic malignancies, and solid tumors.
Strategic partnerships between isotope producers and therapy developers have become the primary mechanism through which developers secure reliable, long-term Ac-225 access, given the structural separation between production and clinical development described above. These agreements typically combine multi-year volume commitments with collaborative technical work to help scale purification and quality processes needed for later clinical phases.
The intensity and structure of these partnerships ultimately trace back to the institutions and customers these companies ultimately serve, since producer and developer strategies are shaped directly by the demand patterns of the buyer ecosystem covered in our end-user and customer segment analysis. As the market matures, expect partnership structures to formalize further, with more producers and developers entering exclusive or preferred-supplier arrangements.
Who are the largest producers of Actinium-225 globally?
Leading producers include NorthStar Medical Radioisotopes, ITM Isotope Technologies Munich, Eckert & Ziegler, and Orano Med, alongside newer entrants such as TerraPower Isotopes, NRG PALLAS, PanTera, and Nusano.
Which companies are furthest along in developing Ac-225-based therapies?
Bayer Radiology, Fusion Pharmaceuticals, RayzeBio, and Telix Pharmaceuticals are among the developers with the most advanced Ac-225-based clinical programs, particularly in prostate cancer.
Are isotope producers and therapy developers typically the same company?
Generally no. The Ac-225 value chain is structurally split between a comparatively small group of specialized isotope producers and a broader set of therapy developers, with only a few organizations spanning both roles.
What kinds of partnerships exist between producers and biopharma developers?
Producers and developers typically enter multi-year supply agreements combining volume commitments with collaborative work on purification and quality processes needed to support later-phase clinical trials.
How is the Ac-225 competitive landscape expected to evolve?
The producer base is expected to broaden further as accelerator-based and reactor-assisted technologies mature, while strategic partnerships between producers and developers are likely to formalize into more exclusive, long-term arrangements.